Report Summary
A hospital-acquired infection (HAI)is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a nosocomial infection (or more generically healthcare-associated infections).
The following market data is provided in this report:
- Market for HAI Diagnostics
- Forecast for HAI Diagnostics to 2015
- HAI Tests on the Market
- Market for Diagnostics by Infection Type (C. Diff., MRSA, Pneumonia, Other)
- Molecular HAI Market vs. Conventional HAI Market, Present and in 2015
- Geographic Breakdown of Testing (U.S., Europe, Asia, ROW)
- New Hospital Infection Product Testing Products in the Market
- Company Profiles
- Treatment Products on the Market, HAI Antibiotic market Size and Forecast
Both diagnostics and treatment segments have unique circumstances for growth which are discussed in detail in the report. Worldwide, both segments combined are worth more than $9 billion for 2010 with 2015 sales expected to reach $10.3 billion. The market has shown an increase of 3% annually with sales increasing from $7.9 billion in 2005. Although the treatment segment will continue to struggle to maintain growth, the testing segment will offset declines beginning in 2012.
This report primarily focuses on bacterial nosocomial infections with some mention of viral infections. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the hospital setting, and b) the practical aspects of diagnosis and therapy are more meaningful based both on medical considerations and on market considerations.
Some of the issues discussed in this report include:
- Development of Potential Life-Saving Products
- Development of Fast Testing Systems
- Growing Drug Resistance
- Development of Better Pharmacodiagnostics
- Market Opportunity and Growth Rates Expected in Diagnostics versus Treatment
- Hospital Procedures for Use of Testing and Antibiotics
- Attention to Special Population Issues
- Demographics and Epidemiology
- New Government Guidelines and Requirements for Preventing Infection
- Focus on Alliances and Partnerships
Market analysis in this report considers primarily the epidemiological considerations and the size of patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing and treatment needs.
The primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends in these product areas. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.
The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, research scientists, business development managers and marketing managers.
Companies profiled in this report are:
- Abbott Laboratories
- AdvanDX
- Alere
- AstraZeneca
- Bayer Schering Pharma
- Becton Dickinson
- Cepheid
- Cubist
- Daiichi Sankyo
- Gen-Probe
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co.
- Meridien
- Pfizer
- Roche
- Seegene